AI in Cardiology: Now and the Road to 2035

AI in cardiology is moving from research toward practical clinical support, especially for ECG interpretation, echocardiography, cardiac MRI, coronary CT, wearables, and catheterization-lab workflows.

Recent reviews report strong performance for detecting arrhythmias, left-ventricular dysfunction, heart failure risk, coronary disease, pulmonary hypertension, and some cardiomyopathies from routine tests. However, performance often falls outside the original development hospital, and many tools still lack prospective outcome evidence.

A 2025 systematic review of randomized trials found only 11 eligible cardiovascular AI trials. Some improved detection, clinical events, or resource use, but the evidence remains too limited to show that AI broadly improves survival.

Notable recent regulatory developments include FDA-cleared ECG-AI tools for detecting risk of cardiac amyloidosis and other structural heart diseases, plus AI-assisted cardiac-MRI planning. These tools generally flag patients for clinician review rather than make autonomous diagnoses.

By 2035, the most likely model is clinician-led, AI-augmented cardiology:
continuous data from ECGs, watches, imaging, electronic records, genomics, and home sensors will feed risk models that identify disease earlier and personalize prevention, monitoring, procedures, and rehabilitation.

Expected 2035 applications include earlier detection of silent atrial fibrillation and heart failure, individualized medication and ablation decisions, AI-assisted imaging and procedural planning, remote management of hypertension and heart failure, and more automated cardiac rehabilitation.

The main constraints are not algorithmic accuracy alone:
bias across populations, privacy and cybersecurity, explainability, liability, workflow integration, regulatory monitoring after deployment, and proof that AI improves patient outcomes rather than merely diagnostic scores.

A realistic forecast is that AI will substantially change cardiology by 2035 but will not replace cardiologists. High-risk decisions, communication, context, and accountability will remain human responsibilities.

Sources:

Pathway Labs Announces World's First FDA Clearance for ...

Artificial intelligence in cardiology: an updated systematic review with ethical considerations and challenges in implementing artificial intelligence models - PubMed

A narrative review on the use of artificial intelligence in cardiovascular medicine - PubMed

Artificial intelligence in cardiology in the current era: a narrative review

Artificial Intelligence in Cardiovascular Medicine - Frontiers

Artificial Intelligence in Cardiovascular Medicine: A Giant ...

Anumana Receives First and Only FDA Clearance for ECG ...

Artificial Intelligence for Cardiovascular Risk Prediction: An Umbrella ...

Randomized Controlled Trials Evaluating Artificial Intelligence in ...

AI in cardiology: level of evidence map - Oxford Academic

Artificial Intelligence in Cardiology: The Current ...

Artificial intelligence in cardiovascular imaging 2025

Atrium Therapeutics Gets FDA Clearance for ATR 1072 IND

Artificial intelligence in cardiovascular care: from promise to ...

Philips SmartHeart receives FDA 510(k) clearance